Dr. Galant received her PhD in medical biophysics from the University of Toronto. She provides expertise in antibody design, immunotherapy, and biochemical immuno-characterization. Dr. Galant was the winner of the inaugural Ted Rogers Centre for Heart Research ECHO 2019 $250,000 pitch competition. She is the recipient of numerous academic fellowships and has co-authored over 15 publications in research areas ranging from chemical informatics to immunotherapy drug development.
Dr. Galant received her PhD from the University of Toronto, where her work helped lead to the development of misTTR, an antibody for the potential treatment of ATTR Amyloidosis, that has since been humanized and entering Phase 2/3 clinical trials. Previous to her work at the University of Toronto, Dr. Galant was the on-site coordinator for the chemical research abroad program and a research associate at the University of Szeged in Hungary.
Fun Fact: Dr. Galant is an avid pinball machine enthusiast and passionate member of the Pinside community
Dr. Sun received his PhD in medical biophysics from the University of Toronto. He provides expertise in neurogenerative protein manipulation and target engagement assays. He leads both antibody design and the development of antibody-mediated immunotherapeutic-mediated clearance assays.
Dr. Sun was the winner of the inaugural Ted Rogers Centre for Heart Research ECHO 2019 $250,000 pitch competition. Dr. Sun was also awarded $165,000 by Brain Canada for his work on ALS. Dr. Sun’s ALS research provided new insights into the formation of TDP-43 protein assemblies in the molecular mechanisms of amyotrophic lateral sclerosis and frontotemporal dementia as his PhD thesis. Dr. Sun also holds an MSc in biochemistry from the University of Toronto.
Fun Fact: Dr. Sun is a connoisseur of rare and fine single malt scotch from Islay
Sandy is an executive with over 30 years of experience in the life sciences industry, where he has extensive and deep relationships with pharma senior R&D and business management executives, as well as the investment community. He currently serves as the President and board member of IMIDomics, Inc as well as Chair of Carisma and non-executive board member of Essa and Compugen (public companies). He has been the CEO or President of five companies (four private, one public), Chair/board member of many public and private companies and has raised over $750 million in capital, and led numerous M&A and licensing transactions.
Fun fact: Sandy was going to become a rabbi.
Dr. Angèle Maki is a business development executive with nearly twenty years of deal-making experience spanning small biotech and big pharma. She is currently Senior Vice President and head of business development at ReCode Therapeutics, a leading genetic medicines company.
Prior to ReCode, Angèle held business development roles with increasing responsibility starting at Medarex followed by BMS (which acquired Medarex), Genentech, 23andMe, Merck & Co, and Eli Lilly. During her career, she has successfully led diligence and negotiations on numerous in - and out- licensing transactions, from early-stage research technologies to clinical-stage assets.
Angèle has a Ph.D. in biological chemistry from Stanford University and completed postdoctoral work in molecular biology at The Scripps Research Institute in La Jolla. She completed her B.Sc. in chemistry at the University of Winnipeg in Canada.
Fun Fact: Dr. Maki owns a Tonal exercise machine which she uses for challenging herself to advanced workouts led by ex-NFL players
Mr. Glinter is the Founder and CEO of Pendant Biosciences, formerly Nanoferix, headquartered in Nashville, TN. He is also the Director of Innovation and Entrepreneurship in the Department of Neurological Surgery and Neuroscience Research at the University of Louisville School of Medicine and an Expert Contributor at the Entrepreneurial Mind.
Concurrently, Mr. Glinter holds a variety of mentorship roles including being a Mentor in Residence at the Wond’ry Center for Innovation and Entrepreneurship at Vanderbilt University, and a Mentor at Life Sciences Tennessee and Jumpstart Foundry. He is also a Master Mentor at the Nashville Entrepreneur Center and at Launch TN. Mr. Glinter founded B&G Holdings to invest in and coach early stage and start up companies. He attended both the University of Maryland College Park and the George Washington University and actively volunteers as a Board Member for a variety of organizations.
Fun Fact: Shawn used to volunteer as a professional clown in children’s hospitals.
Dr. Barry A. Springer, Ph.D., is currently the Principal at Springer Bio-Tech Consulting, LLC, advising early-stage biotechnology companies since 2021. With over 30 years of experience in the industry, he has an accomplished background in small molecule and biologics drug discovery, development, licensing, and technology development.
His career began at DuPont Merck, moving on to be a founding member at 3-Dimensional Pharmaceuticals (3DP). His notable contributions led to the company's acquisition by Johnson & Johnson (J&J). As VP of Enabling Technologies at J&J R&D, he was a member of the leadership team that brought drugs to the clinic, including Invokana.
From 2011 to 2020, Dr. Springer served as VP of Janssen BioTherapeutics, overseeing strategy, operations, and external innovation initiatives. His leadership roles resulted in high-value partnerships, new technologies, and the development of significant drugs such as Rybrevant, Amivantamab for NSCLC, Teclistamab and Talquetamab for multiple myeloma. He earned his Ph.D. in Biochemistry from the University of Illinois and completed his postdoctoral training at U.C. Berkeley.
Fun Fact: Barry is a big Chicago Cubs fan.
Alejandra completed her M.Sc. in Medical Science at the University of Toronto. She brings nearly two years of industry experience in the cell and gene therapy field and over five years of academic research experience in cell and molecular biology. Alejandra's research has focused on using pluripotent stem cells to model Shwachman-Diamond syndrome, a blood disorder, and explore therapeutic approaches for Parkinson's disease, a neurodegenerative condition. At Paradox, she contributes her expertise in stem cell biology to support the development and execution of cell-based assays.
Fun fact: Alejandra loves travelling to Peru and highly recommends hiking Machu Picchu, going off the grid in the Amazon rainforest, sandboarding in the Ica desert, surfing in the beach town of Mancora, and trying all the delicious food in her hometown of Lima!
Dr. Ferro is a former Scientific Officer at Novartis and prior to that a Clinical Team Leader at Sanofi Pasteur. He has extensive experience in vaccine development for infectious diseases and was the Head of Internal Medicine at Hospital Militar in Nicaragua.
Dr. Ferro received his Medical Degree from the Pontificia Universidad Javeriana (Bogata Columbia) and specialized in Internal Medicine. He also holds a Diploma in Clinical Epidemiology from the University of Toronto.
Dr. Hadley completed his PhD in Medical Biophysics at the University of Toronto. He subsequently completed a postdoctoral fellowship and became a scientific associate at the University Health Network in Toronto, Canada. Dr. Hadley has spent more than 18 years exploring the world of protein misfolding, from molecular chaperones to amyloidosis. At Paradox, his responsibilities include candidate design and the development of specialized protein misfolding assays to screen Paradox's misfolding-specific antibodies.
Fun fact: Kevin has been to Iceland five times, but only had to dig his rental car out of a snowdrift once.
Dr. Menon completed his PhD in Biochemistry from Hunter College, City University of New York, NY and a postdoctoral fellowship at the University of Maryland, Baltimore. He brings over 9 years of research experience in the identification and characterization of proteins involved in cancer and retinal diseases. As a scientist at Paradox, he is responsible for the biochemical characterization of lead therapeutic drug candidates.
Fun fact: Besides his love for the outdoors, Dr. Menon has a green thumb and takes a highly scientific approach to gardening and indoor hydroponics
Ryan completed his M.Sc. in Immunology at the University of Toronto. He brings two years of experience in cell-based immunoassays and one year as a lab technician where he processed patient samples and managed research databases. At Paradox, Ryan brings insight into the immunological aspects of Paradox’s drug candidates and to developing cell-based in vitro assays.
Fun fact: Ryan very much enjoys listening to video game soundtracks. He recommends giving the Persona 5 soundtrack a listen for some groovy tunes!
.svg)
.svg)
